Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

TRK Inhibitor Resistance and Safety (19 mins)
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 21, 2020 Expiration: August 20, 2021
Start Activity
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Genentech
George D. Demetri, MD
Program Director
person default
Alexander Drilon, MD
Pashtoon Kasi, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the biology of and rationale for targeting cancers containing NTRK fusions
  • Identify patients with cancer who should be tested for NTRK fusions with established and emerging biomarker assays
  • Describe the research data supporting the use of TRK inhibition in a range of cancers harboring NTRK fusions
  • Formulate strategies for using TRK inhibitors in clinical practice
  • Develop treatment strategies for patients who develop acquired resistance to first-generation TRK inhibitor therapy
  • Refer adult and pediatric patients to ongoing late-phase clinical trials of TRK inhibitors

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

George D. Demetri, MD, has disclosed that he has received consulting fees from AbbVie, AdaptImmune, Bayer, Bessor, Blueprint Medicines, Caprion/HistoGeneX, Caris Life Sciences, Champions Biotechnology, Daiichi-Sankyo, EMD Serono, Epizyme, Erasca, G1 Therapeutics, GlaxoSmithKline, ICON, Ignyta, Janssen, Loxo Oncology, Merrimack, Mirati, MJ Hennessey/OncLive, Novartis, PharmaMar, Pfizer, Polaris, RELAY Therapeutics, Roche/Genentech, Sanofi, Translate BIO, WCG/Arsenal Capital, and ZioPharm and royalties paid to his institution from Novartis.

Faculty

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, BeiGene, BergenBio, Blueprint Medicines, Exelixis, Helsinn, Hengrui Therapeutics, Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, MORE Health, Pfizer, Takeda/Ariad/Millennium, TP Therapeutics, Tyra Biosciences, and Verastem; funds for research support from Foundation Medicine; funds for research support paid to his institution from Exelixis, GlaxoSmithKline, Pfizer, PharmaMar, Taiho, and Teva; and royalties from Wolters Kluwer.
Pashtoon Kasi, MD

Assistant Professor
Department of Oncology
University of Iowa
Iowa City, Iowa

Pashtoon Kasi, MD, has disclosed that he has received consulting fees from Foundation Medicine, Ipsen, Natera, and Taiho (paid to his institution) and funds for research support from Amgen, Array, AstraZeneca, BTG, Clovis, and RenovoRx.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Associate Director, Educational Strategy

Krista Marcello has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians and other healthcare providers who care for patients with cancer.

Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to test for NTRK fusions and integrate TRK inhibitors into the treatment of patients with cancer.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 21, 2020, through August 20, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

TRK Inhibitor Resistance and Safety (19 mins)
  • CME

Alexander Drilon, MD, discusses emerging next-generation TRK inhibitors and their potential use in managing resistance to first-generation agents as well as key adverse events with TRK inhibitors and management strategies.
George D. Demetri, MD
Program Director
person default
Alexander Drilon, MD
Pashtoon Kasi, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: August 21, 2020 Expiration: August 20, 2021

This program is divided into short segments that you can review from the Activity landing page.

Related Content

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD review the role of IO therapy and CRT for early stage NSCLC.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Gain key clinical insights fast, with this short slideset from CCO on new biomarkers driving precision care in lung cancer

Edward S. Kim, MD, FACP Sandip P. Patel, MD Released: October 23, 2020

In this slideset from Clinical Care Options, Jamie E. Chaft, MD and Kristin Higgins, MD provides insights on the latest data on IO therapy for lung cancer.

Jamie E. Chaft, MD Kristin Higgins, MD Released: October 23, 2020

Downloadable slideset with key data from the 2020 ESMO Virtual Congress created by Clinical Care Options (CCO)

Yelena Y. Janjigian, MD Joyce O'Shaughnessy, MD Elizabeth R. Plimack, MD, MS person default Vamsidhar Velcheti, MD Released: October 23, 2020

Video Chapters


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Genentech

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue